AnalystBook Research · Company Intelligence

XOMA Royalty Corp

XOMANasdaq

Built from XOMA Royalty Corp's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Revenue increased 55.6% to $10.3M, while Net income increased 329.4% to $31.7M.

The read at a glance✓ Audited against SEC data
  • Scale — FY2025 revenue $10.3MOK
  • Profitability — Net income $31.7MOK
  • Cash generation — Free cash flow ($96.1M)Note
  • Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
  • Insiders — 1 buys; 1 sells in 365 daysOK
  • Capital — dividends paid were $5.5M; share repurchases were $16.0MNote

Business

XOMA Royalty Corp: Janssen License Agreement ​ The Company's License Agreement with Janssen dated August 5, 2019 LG Chem ​ LG Chem, Ltd Mezagitamab ​ TAK-079, a fully human monoclonal antibody targeting CD38 being developed by Takeda for the treatment of IgA nephropathy and other indications Novartis ​ Novartis Pharma AG, Novartis International Pharmaceutical Ltd., Novartis Institutes for Biomedical Research, Inc. and/or Novartis Vaccines and Diagnostics, Inc.

Where the revenue comes from

Fiscal 2025, as XOMA Royalty Corp reports it. History and quarterly detail are in the app.

  • Single Reportable$52.1M

Leadership changes

From XOMA Royalty Corp's own filings, the day they're filed.

  • Thomas Burns · Chief Financial Officer · departureeff. 2026-01-12
  • Owen Hughes · Chief Executive Officer · appointmenteff. 2024-01-07
  • Jeffrey Trigilio · Chief Financial Officer · appointment

Latest filings

  • 8-K · Company announcement2026-07-14
  • 8-K · Company announcement2026-06-12
  • 8-K · Company announcement2026-05-22
  • 8-K · Company announcement2026-05-18
  • 10-Q · Quarterly report2026-05-12
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about XOMA Royalty Corp, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full XOMA record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.